Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

Inclusion Criteria: * Age ≥18 years at the time of dalbavancin treatment initiation * Male and female patients * Patients who received dalbavancin as targeted or empirical therapy to treat Gram-positive bacterial infection or as anti-Gram-positive component of a treatment regimen for mixed infection (e.g., with concurrent antibacterial or antifungals drugs for covering Gram-negative strains or fungi) * Patients who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study * Patients with known type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) at the time of infectious disease of interest diagnosis * Patients with available retrospective data in medical charts, including information about dalbavancin treatment and diabetes history * Patients who gave informed consent and personal data processing consent to take part into the study following local regulation. Exclusion Criteria: * Patients enrolled in a clinical trial in which treatment with dalbavancin was managed through a study protocol * Patients diagnosed with any hyperglycemic state other than T1DM or T2DM at the time of dalbavancin treatment initiation * Patients with long-term infection (over than 12 months of duration) at the time of dalbavancin treatment initiation * Previous participation in this study. Participation is defined as having given informed consent in this study * Pregnant or breast-feeding patients from start time of dalbavancin treatment initiation till enrolment visit.